目的探讨蛋白酪氨酸激酶抑制剂抗肿瘤作用机理及其研究进展。
Objective To approach the mechanism of action of anticancer and the investigation progress of protein tyrosine kinase (PTK).
结论:在苦参碱诱导K562细胞分化的过程中,涉及到蛋白酪氨酸激酶的活性改变。
Conclusions: the change of protein tyrosine kinase activity is involved in the differentiation of K562 cells induced by matrine.
吉非替尼为一种选择性的EGFR一蛋白酪氨酸激酶抑制剂,能阻断酪氨酸蛋白激酶信号传导通路,从而促进肿瘤细胞凋亡。
Gefitinib is protein tyrosine kinase inhibitor of a selective EGFR, can block the signal transduction pathway of tyrosine protein kinase, and then promote tumor cell apoptosis.
因此,本研究的目的是调查金雀异黄素,一种蛋白质酪氨酸激酶抑制剂,对有急性或慢性糖尿病炎症小鼠(诱导脲佐菌素)的影响。
Therefore, the aim of this study is to investigate the effects of genistein, a protein tyrosine kinase inhibitor, on acute and chronic inflammation in diabetic mice (induced by streptozotocin).
包括单克隆抗体、酪氨酸激酶抑制剂、融合蛋白、瘤苗在内,以her2为靶点的抗肿瘤治疗研究成为热点,并显示出广阔的应用前景。
Anticancer therapies targeting HER2 have shown promise and become a focus, including monoclonal antibody, tyrosine kinases inhibitor, tumor vaccine, fusion protein.
酪氨酸激酶型受体、G蛋白偶联受体和离子通道型受体是细胞表面三类主要受体。
Receptor tyrosine kinases (RTK), G protein-coupled receptors (GPCR) and ion channel receptors are main cell surface receptors.
经尿素变性、梯度透析复性及去除GST“标签”后,获得重折叠的人EGFR胞内酪氨酸激酶结构域蛋白。
After denaturing in urea, gradient dialysis and cleavage of GST-tag, refolded human EGFR-TKD was obtained.
鉴定了分子量为130000酪氨酸磷酸化的蛋白质为JAK2,一种非受体型酪氨酸激酶。
The tyrosine phosphorylated 130000 protein was identified as JAK2, a non receptor tyrosine kinase.
鉴定了分子量为130000酪氨酸磷酸化的蛋白质为JAK2,一种非受体型酪氨酸激酶。
The tyrosine phosphorylated 130000 protein was identified as JAK2, a non receptor tyrosine kinase.
应用推荐